BCAL Diagnostics Ltd (ASX: BDX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
BCAL Diagnostics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
BCAL Diagnostics Ltd (ASX: BDX)
Latest News

Healthcare Shares
'Breakthrough results': Why this ASX healthcare share just exploded 160%

Healthcare Shares
3 ASX health care shares that outpaced the market on Friday
BDX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About BCAL Diagnostics Ltd
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.
BDX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
28 Nov 2023 | $0.10 | $0.00 | 0.00% | 218,750 | $0.10 | $0.10 | $0.10 |
27 Nov 2023 | $0.10 | $0.00 | 0.00% | 239,090 | $0.10 | $0.10 | $0.10 |
24 Nov 2023 | $0.10 | $-0.01 | -9.09% | 373,170 | $0.11 | $0.11 | $0.10 |
23 Nov 2023 | $0.11 | $0.00 | 0.00% | 281,702 | $0.11 | $0.11 | $0.11 |
22 Nov 2023 | $0.11 | $0.00 | 0.00% | 135,457 | $0.14 | $0.15 | $0.11 |
21 Nov 2023 | $0.11 | $0.00 | 0.00% | 55,472 | $0.11 | $0.11 | $0.11 |
20 Nov 2023 | $0.11 | $0.01 | 10.00% | 364,364 | $0.10 | $0.12 | $0.10 |
16 Nov 2023 | $0.10 | $0.00 | 0.00% | 239,047 | $0.11 | $0.11 | $0.10 |
14 Nov 2023 | $0.11 | $0.00 | 0.00% | 253,334 | $0.11 | $0.11 | $0.10 |
13 Nov 2023 | $0.11 | $0.01 | 10.31% | 70,816 | $0.10 | $0.11 | $0.10 |
10 Nov 2023 | $0.10 | $0.00 | 0.00% | 295,707 | $0.10 | $0.10 | $0.10 |
09 Nov 2023 | $0.10 | $0.00 | 0.00% | 130,000 | $0.10 | $0.10 | $0.10 |
08 Nov 2023 | $0.10 | $0.00 | 0.00% | 100,000 | $0.10 | $0.10 | $0.10 |
07 Nov 2023 | $0.10 | $-0.01 | -9.52% | 1,452,981 | $0.11 | $0.11 | $0.10 |
06 Nov 2023 | $0.11 | $0.00 | 0.00% | 500,000 | $0.11 | $0.11 | $0.11 |
02 Nov 2023 | $0.10 | $0.00 | 0.00% | 12,950 | $0.10 | $0.10 | $0.10 |
01 Nov 2023 | $0.10 | $0.00 | 0.00% | 215,000 | $0.10 | $0.10 | $0.10 |
31 Oct 2023 | $0.10 | $0.00 | 0.00% | 55,621 | $0.11 | $0.11 | $0.10 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
24 Nov 2023 | Mark Burrows | Issued | 300,000 | $30,000 |
Placement.
|
24 Nov 2023 | Jonathan Trollip | Issued | 200,000 | $20,000 |
Placement.
|
23 Nov 2023 | Ronald (Ron) Phillips | Exercise | 2,022,638 | $116,099 |
Exercise of options.
|
23 Nov 2023 | Ronald (Ron) Phillips | Buy | 2,022,638 | $116,099 |
Exercise of options.
|
23 Nov 2023 | Jayne Shaw | Exercise | 2,022,638 | $116,099 |
Exercise of options.
|
23 Nov 2023 | Jayne Shaw | Buy | 2,022,638 | $116,099 |
Exercise of options.
|
23 Nov 2023 | Jonathan Trollip | Buy | 1,155,793 | $66,343 |
Exercise of options.
|
23 Nov 2023 | Jonathan Trollip | Exercise | 1,155,793 | $66,343 |
Exercise of options.
|
18 Sep 2023 | Merilyn Sleigh | Buy | 200,000 | $20,000 |
Participation in share purchase plan.
|
18 Sep 2023 | Jonathan Trollip | Buy | 300,000 | $30,000 |
Participation in share purchase plan.
|
18 Sep 2023 | Jayne Shaw | Buy | 300,000 | $30,000 |
Participation in share purchase plan.
|
18 Sep 2023 | Ronald (Ron) Phillips | Buy | 157,746 | $15,774 |
Participation in share purchase plan.
|
18 Sep 2023 | Ronald (Ron) Phillips | Buy | 142,254 | $14,225 |
Participation in share purchase plan.
|
18 Sep 2023 | Mark Burrows | Buy | 300,000 | $30,000 |
Participation in share purchase plan.
|
02 May 2023 | Merilyn Sleigh | Buy | 45,000 | $4,095 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Mark Douglas Irving Burrows | Non-Executive Director | Jul 2021 |
Mr Burrows is an advocate for early diagnosis of breast cancer and other cancers. He has enjoyed a long and distinguished career in investment banking both in Australia and the UK. Mr. Burrows cofounded Baring Brothers Burrows & Co in Australia in the early 80s. In 1999 he was appointed the Managing Director/Deputy Chairman of ING Barings in London. In 2004, Mark joined Lazard as a Managing Partner and in 2006 returned to Australia and was appointed Lazard Australia's inaugural Chairman. Mr. Burrows returned to investment banking in 2011 as Vice Chairman of Credit Suisse's Global Investment Bank. During his investment banking career, Mr. Burrows has been the principal financial advisor to some of the corporate and government transactions in Australia. Mr Burrows is a member of Risk Management Committee.
|
Ms Jayne Andrea Shaw | Executive ChairmanExecutive Director | Feb 2010 |
Ms Shaw is Trained as a Registered Nurse in the UK, on arrival in Australia Jayne became a Director of Nursing and Chief Executive Officer of two private hospitals. Following this, she established an Australian and international consulting business which was sold to Healthsouth a US Healthcare company. Ms Shaw has been a member of a number of private healthcare boards involved with specialist consolidation including cardiology, orthopaedics, and women's health, and continued to work with private equity firms on local and International Healthcare transactions.
|
Dr Merilyn Joy Sleigh | Non-Executive Director | Mar 2021 |
Dr. Sleigh has over 30 years of experience as a senior executive and non-executive director in Australia's biotechnology sector. Dr Sleigh was, from its foundation, Chief Executive Officer and Managing Director of EvoGenix Limited, a biotech startup company that internationally and listed on the ASX before acquisition by a larger company, resulting in attractive returns for its investors. Dr. Sleigh was formerly Dean of the Faculty of Life Sciences, University of NSW; Director of Research & Development at Australian biotech Peptech Ltd and a research scientist and senior manager with CSIRO. Dr Sleigh has held non-executive director positions with ASX listed companies Clover Corporation, and Tyrian Diagnostics Ltd. as well as with Adalta Ltd and Mimetica Pty Ltd. Other director roles have been with government and not for profit organisations, including the Rural Industries Research and Development Corporation and Relationships Australia. She has acted as an adviser and consultant to companies, government, research institutes and investors on technology commercialisation.
|
Mr Jonathan Alfred Grey Trollip | Non-Executive Director | Dec 2020 |
Mr Trollip is a experienced professional non-executive Director with over 30 years of commercial, corporate, governance and legal and transactional expertise. Mr Trollip was previously a director of Propel Funeral Partners Limited (19/9/2017 to 6/5/2022) and Yellow Holdings Limited (5/12/2019 to 1/4/2023). He has a interest in the not-for-profit sector and is involved at Board level and a contributor with various not for profit organisations in Australia and Southern Africa in the education sector and in wildlife conservation. Mr Trollip is the Chair of Risk Management Committee.
|
Hon Ronald (Ron) Anthony Phillips | Non-Executive Director | Feb 2010 |
Mr Phillips has 15 years in the NSW Parliament which included serving as Minister for Health and Deputy Leader of the Opposition, Mr Phillips developed a consulting business in the Health and Aged Care Industry. His business interests included co-owner and Managing Director of Sydney Breast Clinic which he sold to Healthscope. He recently retired as Chair of the Sydney Local Health District and as Director of Westmead IVF. Mr Phillips has had no other listed entity directorships in the last three years. He is Member of Risk Management Committee
|
Mr Guy Adrian Robertson | Chief Financial OfficerCompany Secretary |
-
|
|
Dr John Hurrell | Chief Executive Officer | Feb 2022 |
-
|
John Hurrell | Chief Executive Officer |
-
|
|
Guy Adrian Robertson | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Nabelle Pty Ltd <The Shaw Super Fund A/C> | 19,162,405 | 7.97% |
Ann-Marie Phillips | 16,574,988 | 6.90% |
Capital Property Corporation Pty Ltd <Carrington A/C> | 15,193,425 | 6.32% |
Mera Vale No 1 Pty Ltd <Mera Vale No 1 A/C> | 11,593,215 | 4.82% |
The Trust Company (Australia) Limited <Mbf A/C> | 11,400,000 | 4.74% |
Ronald Anthony Phillips | 8,260,604 | 3.44% |
The Trust Company (Australia) Limited <Mof A/C> | 7,830,298 | 3.26% |
Coolbrun Pty Ltd <The Coolbrun Family A/C> | 6,633,789 | 2.76% |
Nabelle Pty Ltd <The Shaw Family A/C> | 6,115,172 | 2.54% |
Carwoola Pastoral Co Pty Ltd | 4,424,895 | 1.84% |
John Hurrell | 4,200,000 | 1.75% |
Angelo Korsanos & Antonia Korsanos <Korsanos Family A/C> | 3,484,050 | 1.45% |
Vintage Dawn Pty Ltd <Jamie + Caroline Odell S/F> | 3,484,050 | 1.45% |
Piaster Pty Ltd <Trollip Family S/F A/C> | 3,447,649 | 1.43% |
Citicorp Nominees Pty Limited | 3,378,611 | 1.41% |
Sean Kennedy | 3,300,303 | 1.37% |
Mera Vale No 1 Pty Ltd II<Mera Vale No 1 A/C> | 3,200,000 | 1.33% |
Darville Pty Limited | 3,101,660 | 1.29% |
Scapa Pty Ltd <The Scapa A/C> | 3,048,563 | 1.27% |
Innovative Management Pty Ltd <Thn Family Office A/C> | 3,000,000 | 1.25% |
Logitix Pty Ltd <Smith Family A/C> | 2,742,025 | 1.14% |